Published online Dec 9, 2014. doi: 10.5497/wjp.v3.i4.186
Revised: July 4, 2014
Accepted: September 17, 2014
Published online: December 9, 2014
Core tip: Thrombocytopenia associated with liver disease is multifactorial. Eltrombopag, a thrombopoietin agonist, has been found useful in increasing platelet counts in these patients. It has been clinically used to increase platelet counts in cirrhotic patients prior to invasive procedures and in patients with chronic hepatitis C to enable administration of interferon based antiviral therapy. However, there are concerns regarding its safety and possible increased risk of portal vein thrombosis.